巴曲酶联合依达拉奉治疗进展型脑梗死44例临床疗效分析  

United batroxobin edaravone treatment of progressive clinical analysis of 44 cases of cerebral infarction

作　　者：周启才[1] 林泽鹏[2] 

机构地区：[1]深圳市宝安区松岗人民医院药剂科,广东深圳518105 [2]深圳市孙逸仙心血管医院心内科,广东深圳518020

出　　处：《四川医学》2011年第6期899-900,共2页Sichuan Medical Journal

摘　　要：目的观察巴曲酶联合依达拉奉治疗进展型脑梗死的临床治疗效果。方法 88例发病时间6～72h的进展型脑梗死患者随机分为观察组和对照组各44例,两组均给予常规治疗,同时观察组应用巴曲酶联合依达拉奉治疗,对照组加用巴曲酶治疗,疗程结束后比较两组的疗效及不良反应情况。结果观察组的总有效率为93.18%,对照组的总有效率为79.55%,两组疗效经检验,差异有统计学意义(P<0.05)。两组疗程结束后神经功能缺损评分均低于治疗前,且观察组显著低于对照组,经统计学分析显示,差异有统计学意义(P<0.05)。观察组未见明显不良反应发生。结论巴曲酶联合依达拉奉治疗进展型脑梗死疗效明显,无明显不良反应,安全、可靠,值得推广应用。Objective To observe the Batroxobin progress in the United edaravone treatment of cerebral infarction.Methods88 patients with onset of the progress of 6～72h cerebral infarction were randomly divided into two groups and the control group 44 patients in both groups were given conventional treatment,while the observation group Batroxobin United edaravone treatment group plus batroxobin treatment,after treatment were compared the efficacy and adverse effects.ResultsThe total effective rate of the observation group 93.18%,total effective rate of the control group 79.55%,Х^2 calculated by the two groups,the difference was significant（P〈0.05）.Two groups of neurological function after treatment were lower than before treatment assessment,and the observation group were significantly lower than the control group,the statistical analysis showed significant difference（P〈0.05）.Observation group no significant adverse reactions.ConclusionBatroxobin United edaravone treatment of progressive cerebral infarction was no obvious side effects,safe,reliable,should be widely applied.

关 键 词：巴曲酶 依达拉奉 进展型脑梗死 

分 类 号：R743.3[医药卫生—神经病学与精神病学]